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Background. Multiple Sclerosis (MS) is a chronic neurological disorder caused by neurodegeneration within the central nervous
system. It results in impaired physical, cognitive, and psychological functioning and can also lead to lower urinary tract symptoms
including nocturia.While clinical trials have suggested an association between nocturia andmelatonin secretion, to our knowledge,
no qualitative research has been conducted on the experience of taking melatonin to treat nocturia in progressive MS within a
clinical trial. Methods. 17 semistructured qualitative interviews were conducted as part of a double-blind, randomised, placebo
controlled, crossover, clinical trial with consenting adults with MS. Interviews explored participants’ experiences of nocturia
associated with MS and their experience of taking melatonin as a trial treatment for nocturia versus a placebo. Data was analysed
using a thematic analysis. Results. Themes on the experience of nocturia revealed participants’ understandings of nocturia, the
impact it had on their night, and increased daily fatigue.Themes on the intervention showed perceived improvements to nocturia,
sleep, and energy and negative effects including lethargy, a lack of significant change, and physical side effects including vivid
dreams. Conclusion. This qualitative exploration revealed an association between nocturia and increased levels of fatigue during
the day by those with MS. However, perspectives towards the effectiveness of melatonin as a potential treatment varied as both
placebo and melatonin were perceived as having very similar effects.
1. Introduction
Multiple Sclerosis (MS) is a chronic neurological disease
which affects over 100,000 people in the UK [1]. It is char-
acterised by progressive neuronal degeneration secondary to
neuroinflammation within the central nervous system often
resulting in impaired physical, cognitive, and psychological
functioning and the presentation of a range of different,
unpredictable symptoms. Such neurodegenerative diseases
are also known to damage the neuronal pathways involved
in lower urinary tract control [2]. As a result, people with MS
often report a range of lower urinary tract symptoms (LUTS)
including hesitancy, retention, urgency, incontinence, fre-
quent urination, and nocturia [3, 4].
Nocturia is a common condition and is defined by the
International Continence Society (ICS) as the “need to wake
one or more times at night to void” [5]. It is frequently
cited as one of the most bothersome urinary symptoms and
can have a significantly adverse effect on quality of life [6].
This perception often increases with the number of sleep
disturbances per night [7]. For those with MS, consistently
waking up to pass urine during the night can be a significant
concern especially when suffering from advanced disease.
In such situations, physically getting up to urinate can be a
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physical challenge in itself, leading to falls and potentially
disrupting the sleep of their carers and/or family member.
Disrupted sleep can also exacerbate the experience of
fatigue during the day. This is particularly important as
fatigue is considered one of the most troublesome MS
symptoms and can have a detrimental effect on quality of life
[7]. It interferes with an individual’s ability to partake inmany
daily activities and is also closely correlated with depression
[8]. Though the causes of MS related fatigue are relatively
unknown, sleep disturbances such as nocturia undoubtedly
contribute to its severity. Positive correlations have been
found between waking during the night and the presences of
fatigue during the day and respondents identified nocturia as
a key contributing factor [9].
Melatonin, a hormone secreted primarily at night, reg-
ulates circadian rhythms and reduces spontaneous smooth
muscle activity including that in the bladder [10]. Melatonin
secretion can be impaired in MS and it was hypothesised
that its administration could improve nocturia among indi-
viduals with MS [11]. It has been evaluated in elderly people
and men as a potential treatment for nocturia [12, 13].
The present double-blind, randomised, placebo controlled,
crossover clinical trial sought to extend these findings to indi-
viduals with MS by assessing the effectiveness of melatonin
on the number of nocturia episodes per night. The current
report describes the qualitative phase of the study with a
particular focus on the lived experience of nocturia from the
perspective of adults with progressiveMS, and where possible
their partners. It will also discuss the experience of taking
melatonin and a placebo for the treatment of nocturia while
participating in the trial.
2. Materials and Methods
2.1. Overview. This qualitative exploration was embedded
within a double-blind, placebo controlled, randomised con-
trolled, crossover trial of melatonin for the treatment of
nocturia in adults with Multiple Sclerosis (MeNiMS) [11].
This consisted of two treatment periods which involved
administering the intervention drug melatonin for six weeks
and the placebo for a further six weeks with a one month
wash out period between each treatment phase. The order of
administration was randomised and consenting participants
were given 2mg per night of sustained-release melatonin
(Circadin) or a placebo capsule, identical in appearance to
Circadin, per night. During the trial, participantswere invited
to take part in five study visits to monitor progress and
were interviewed by a qualitative researcher following their
final study visit. This was approved by the National South
West Research Ethics Committee, Exeter, UK (REC reference
number: 12/SW/0322).
2.2. Participants. Patients with MS were recruited to the
MeNiMS trial fromNorth Bristol NHS Trust with the follow-
ing inclusion criteria: (1) aged over 18, (2) having diagnosed
MS according to McDonald criteria, (3) having at least one
episode of nocturia per night as defined by ICS, and (4)
female subjects of childbearing potential having to be willing
Table 1: Demographic details for qualitative study participants.
Variable Values
Gender
Male 7
Female 10
Age, y
Range 39-67
Mean 58
Ethnicity (n)
White 15
No response 2
Employment Status (n)
Working 5
Not working 3
No response 9
Education (n)
Left school at 16 or younger 2
Left school at 17 or 18 1
College or further education 4
Graduated from university 6
No response 4
Type of MS (n)
Secondary Progressive MS 9
Primary Progressive MS 2
Relapsing Remitting MS 6
to use an effective method of contraception throughout the
study. Eighteen participants from the total MeNiMS trial
population were approached for the qualitative interview and
seventeen provided written consent. The sample consisted of
ten female participants and seven males with an age range
of 39 to 67 (mean: 58 years). Six patients had Relapsing
RemittingMS (RRMS), twoPrimary ProgressiveMS (PPMS),
and nine Secondary Progressive MS (SPMS). The sociode-
mographic characteristics of participants are presented in
Table 1. Clinical quantitative data regarding EDSS (Expanded
Disability Status Scale), quality of life associated withMS and
nocturia, bladder dysfunction, and sleep quality evaluation
are detailed by treatment groups in the primary trial outcome
paper [14].
2.3. Data Collection
2.3.1. Semistructured Interviews. Prior to their final study
visit, consenting participants were contacted by the qual-
itative research team via telephone and were given the
opportunity to discuss the qualitative study. In total, seven-
teen semistructured face to face interviews were conducted
and where possible, the partners of participants were also
involved in these discussions. Interviews took between 20 and
40 minutes to complete and were facilitated by a topic guide
(Box 1) that was specifically designed to elicit an exploration
of the following qualitative research aims:
(1) Explore patients’ (and partners’) perspectives of noc-
turia associated with progressive MS.
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MeNiMS interview schedule 06/12
(1) Explore the patient and partner’s perspective of nocturia associated with progressive MS.
(2) Explore perceptions of the intervention on nocturia and associated quality of life impact from the patient
and partner’s perspective.
Intervention exploration
(i) Describe experience of nocturia/waking at night to urinate before this trial
(a) How often?
(b) How do you feel about it?
(c) What impact does this have on day-to-day life?
(ii) How have these symptoms been during this trial?
(iii) What has your sleep experience been like during the trial?
(iv) Did you notice any differences between the first period and the second period of medication?
(v) What about the period in between when you were not taking any trial medication?
(vi) What have been the main advantages of taking the study medication?
(vii) What have been the main disadvantages of taking the study medication? Did you notice any side-effects at all?
Questions for partners:
Could you talk a bit how your partner’s nocturia impacts on your sleeping?
And your lifestyle?
And during the course of the trial how has it been for you?
Box 1: Topic guide for qualitative interviews.
(2) Explore perceptions of the intervention on nocturia
and associated quality of life impact from the patients’ (and
partners’) perspective.
2.4. Thematic Analysis. All interviews were audio recorded
and the data was transcribed verbatim. Transcripts were then
coded using NVivo 10 and analysed using a thematic analysis
[15]. Based on recommendations by Braun and Clarke [15], an
inductive approach to analysis was incorporated. Transcripts
were read and reread multiple times to allow an in depth
familiarisation with the data. Important aspects of the data
were then identified and coded descriptively and synthesised
into themes. Finally, the first author was unblinded and
themes were reviewed in light of the order of treatment to
ensure an accurate understanding of participants’ experi-
ences regarding the effectiveness of melatonin. All themes
were divided into two key concepts which reflected both
research questions.
3. Results
A total of five themes and fourteen subthemes were found
(Figure 1) and grouped into two key categories to reflect the
research questions.
These categories were “participants” perspectives of noc-
turia’ and “participants” perceptions of the intervention’.
3.1. Part 1: Perspectives ofNocturia. Three overarching themes
emerged in relation to participant’s perspectives of nocturia
and their experience of this urinary symptom: (a) under-
standing nocturia, (b) a disrupted night, and (c) aggravated
fatigue. Further to this, a number of interconnected sub-
themes were also explored.
3.1.1. Theme 1: Understanding Nocturia
Recognising the Problem. Several participants had struggled
to recall the precise onset of nocturia and described it as a
progressive, gradual symptom that had increased in severity
in recent years. Some participants viewed it as a sign of their
transition into older age; a view that was strengthened by its
prevalence within social circles. Participants also emphasised
the role of the trial in enabling them to develop a better
understanding of this relatively unknown symptom.
“You think it’s not just me then, everybody seems
to be getting up in the middle of the night”
(Participant 022)
“I suppose still in the back of my mind I was
thinking this is going to clear up it was only when
they suggested going on the trial and now I think
well there is a problem” (Participant 032)
Managing Nocturia. Nocturia was perceived as another
symptom which heightened the challenging nature of MS
and fatigue. Thus, participants stressed the importance
of preventing the symptom from further hindering their
daily activities. Individuals incorporated various manage-
ment techniques into their lives (e.g., restricting their liquid
intake) and it was noted that trial participation resulted in a
better understanding of their nocturia which assisted in the
development of coping strategies.
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Figure 1: Summary of qualitative themes and subthemes.
“It gets too urgent and then you can’t control your-
self so you have to go but your body’s forcing you
out of bed no matter what you do” (Participant
001)
“I think most people get up once or twice and it’s
manageable isn’t it but it’s not manageable when
it’s five, six times a night” (Participant 005)
Abnormality. Participants described their gradual realisation
that their need to wake up to pass urine was problematic.
For participants, nocturia had gradually worsened resulting
in negative daily consequences. Moreover, the symptom was
increasingly associated with a feeling of being different; an
already prevalent feature of their life. It was noted that it was a
desire for “normality” that had motivated them to participate
in the trial and treat nocturia.
“My husband doesn’t get up during the night,
friends, if I’m on holiday with them they don’t and
it’s like how come I do?” (Participant 029)
3.1.2. Theme 2: A Disrupted Night
A Pattern of Disturbance. Nocturia was described as a regular
occurrence and would often occur at consistent times during
the night. This varied between participants but an individual
pattern was commonly reported with most participants
agreeing that the initial disturbance would take place a few
hours following initiation of sleep. Participants had felt that
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the disturbances would coincide with their attempts to fully
engage in deep sleep.
“It was happening at half past four in the morning
every night and I thought well that is a problem
because that's when you should be deeply in sleep”
(Participant 023)
Reduced Quality of Sleep. All participants reported a broken,
disrupted sleep experience which contributed to an overall
sentiment that nocturia had substantially interfered with the
quality of sleep. Both partners and participants provided
detailed descriptions of poor sleep and estimated that waking
to pass urine reduced their sleeping hours.
“I’m getting up four times a night I mean that’s
four hours of my total sleep gone” (Participant
030)
“It’s so rare that he really gets a good night’s sleep;
I don’t think there are any nights that you don’t get
up at all” (Partner of Participant 001)
Impact of Being Awake during the Night. Participants detailed
their experience of being awake during the night due to noc-
turia. Urinary hesitancy, urgency, and incomplete emptying
meant that passing urine during the night was often a drawn-
out experience. Participants with mobility issues specified
that this could potentially result in injury as participants felt
disoriented when awake in the night. Almost all participants
recalled anxiety and frustration as they began to antici-
pate a negative daily impact. Some had also incorporated
distraction methods to initiate sleep such as meditation,
reading books or watching television which was also used as
a mechanism to prevent disruptions to their partners’ sleep.
This was a specific concern, as some participants explicitly
described the guilt and embarrassment that they felt as they
recalled disturbing others.
“Every time I’d even gone away to the loo and came
back and got into bed I felt like I wanted to go
again. It was really, really annoying” (Participant
005)
“I mean he [partner] is a shift worker so he doesn’t
get enough sleep sometimes anyway because of his
shift patterns and for me then to disturb him, I
don’t like doing that it’s not fair” (Participant 004)
“I think I’m quite a light sleeper so [021]’s quality
of sleep generally affects mine” (Partner of Partic-
ipant 021)
3.1.3. Theme 3: Aggravating Fatigue
A Debilitating Symptom. Of all the symptoms reported by
participants, fatigue was considered the most debilitating and
was interlinked to the tiredness caused by nocturia. As their
day began, participants described overwhelming feelings of
tiredness which were primarily attributed to nocturia. They
lacked energy and motivation and this was a barrier to
maintaining their day to day lives. Those in employment
required flexible working hours as waking up at certain times
was difficult. Some would participate in shift work, drink
caffeine when necessary or sleep in short periods throughout
the day. Fatigue also negatively affected the interpersonal
lives of participants as they struggled to interact in social
situations.
“Fatigue, that’s the issue but that’s caused some-
times because I’m not getting the right amount
of sleep as well which doesn’t help so it’s the two
together really” (Participant 004)
“It’s a pain, it makes you worse the following day
you never have the energy you’re more irritable
and you don’t have the energy to function in the
way that you’d like to function like probably most
people do by not getting up to the loo all night long”
(Participant 002)
Psychologically Challenging. Participants also described the
substantial psychological effect as they reported feelings of
anxiety and embarrassment. They concluded that the com-
bination of fatigue and severe tiredness resulted in anxiety,
depression, low mood and irritability. This consequently
affected motivation as participants expressed a fear of par-
taking in new activities. Participants also felt that it caused
cognitive difficulties resulting in embarrassment.
“I think the worse thing with MS is the frustration
because you want to do something and that
you’re just limited because of your energy levels”
(Participant 033)
“If I have a bad night’s sleep and I've got an
appointment in the morning then that creates
another level of anxiety because I know that if I
don't process everything properly then it could be
very, very embarrassing” (Participant 022)
3.2. Part 2: The Intervention. Data that emerged during
discussions on the effectiveness of the intervention was coded
into two key themes that aptly captured the participants’
perspectives. All participants essentially summarised positive
and negative experiences and as such all themeswere grouped
into either “perceived improvements” or “adverse effects”
accompanied by subthemes.
3.2.1. Theme 1: Perceived Improvements
Reduction in Nocturnal Voiding. A total of nine participants
reported a reduction in nocturnal voiding when taking mela-
tonin. However, one respondent specified that this had been
a temporary improvement and their outcome measurements
showed they experienced a more substantial improvement
while taking the placebo. In fact, four respondents described
urinary improvement when taking placebo. The perceived
reductions ranged from twice nightly to a total reduction in
nocturnal voiding. These changes were viewed as positive if
they enabled participants to better manage their sleep.
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“This is brilliant but after about four, five or six
days they came back and then it was once a night”
(Participant 022 – placebo)
“Because it’s once or twice you can then get back to
bed . . . you suddenly go back to sleep” (Participant
002 - melatonin)
Better Sleep. Improvements to the subjective experience of
sleep were specifically described by six participants while
taking melatonin. A further two participants noted that
melatonin had helped induce a feeling of restfulness that
resulted in a deeper sleep and made initiating sleep much
easier. Two participants had also discussed this change while
taking a placebo. For the participants who had reported fewer
incidences of nocturnal voiding during the night, the lack
of disruptions allowed them to engage in deeper sleep for a
longer period.
“I’m dropping off to sleep easier [than] before and
I am also going back to bed and going to sleep, it’s
quite a big improvement. I feel better, I don’t feel
so foggy” (Patient 032 - melatonin)
“From memory I didn’t get up at all but as I said
when I did I could go to the loo come back and
think right I’m just going to go straight to sleep
now and I did and that was good” (Patient 004
- melatonin)
“The quality of sleep is a lot better and because the
quality of sleep’s a lot better I feel a lot better I've
got more energy I just felt great” (Patient 030 –
placebo)
Higher Energy Levels. Most participants who had reported
positive changes to sleep also articulated that this had caused
significant improvements to their emotional state and they
recalled a better mood, more enthusiasm throughout the
day and a significant increase in perceived energy levels
and mental alertness. This resulted in positive interpersonal
changes that were visibly noticeable as two participants also
recalled the positive feedback that they received from family
memberswhile taking melatonin. In total, these changes were
reported by six participants during the melatonin phase and
three while taking placebo.
“He’s happier when he wakes up; it makes a
difference in the day” (Partner of Patient 002 -
melatonin)
“Brilliant. . . more va va voom, gives you more
energy I suppose from not constantly being inter-
rupted going to the toilet during the night and solid
sleep which is lovely” (029 - placebo)
3.2.2. Theme 2: Negative Effects
A Lack of Change. For respondents, one phase was often
characterised by a continuation of their pretrial symptoms
and the common belief was that this was the placebo. Partici-
pants reporting this during the first part of the trial remained
hopeful that the second drug would be far more effective
and would result in the improvements that they desired.
However, those who had experienced positive changes when
taking melatonin during the first phase reported a slow
progressive decline in improvements during their placebo
phase. They specified that it was during the final week of this
phase that their pretrial symptoms had completely returned.
Three participants also reported that neither drug had been
particularly effective.
“These last lot I’ve had over the last four weeks
I’ve been awake quite often during the night and
they’ve just done nothing to be honest with you I
haven't noticed anything” (Patient 004 – placebo)
“I could have been on the placebo both times really,
I didn’t notice enough to go wow that’s made a
difference” (Patient 003 – both phases)
Exhaustion. For seven participants, the trial had been partic-
ularly challenging as they experienced exhaustion, tiredness
and an increased desire to sleep. For some this was more
severe, while others described it as a slight increase in
tiredness. Five of these reports were relayed by participants
when taking melatonin which was thought to have induced
a feeling of sleepiness that made it much more difficult for
these participants to wake up in the morning. This tiredness
continued throughout the day and was described in different
ways, most commonly as drowsiness. This intensified the
negative emotions reported by participants who felt more
irritable.
“I found it hard to come round in the mornings, I
don’t think I went off to sleep much quicker may
be a bit but it was really in the mornings that I
tend to notice the thick headedness and difficulty
waking up” (Patient 027 - melatonin)
‘I felt more lacklustre and lost energy on the
second drug than I normally did’ (Participant 021
– Placebo)
“The last three or four weeks I’ve been very
irritable. . . my concentration’s gone. I can’t seem
to want to read, I normally read and I don’t read
so much. I’ve got no interest in films. . . very little
I like to do now that I get enjoyment from. . . It
doesn’t seem to be to do with the MS it just feels
like the drug” (Patient 023 - melatonin)
Unusual Side Effects. A number of physical effects were
perceived as unusual and unexpected by respondents and
these appeared to be prevalent when taking either drug.
This consisted of two isolated reports of physical sensations
including headaches and dizziness when individuals began
taking melatonin and one report of a strange taste while
taking the placebo. Themost commonly discussed side effect
however was vivid dreams as four participants reported this
experience while taking melatonin and two while taking the
placebo.
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“I had some very strange sort of headaches, it
was almost like pins and needles for a couple of
days when I first started taking them like sort of
currents almost in my head and then when I was
coming off for a couple of days of not taking them
I sort of had just this funny head” (Patient 004 -
melatonin)
“The first two nights I had very vivid dreams I
remember that. . . yeah I do talk anyway in my
sleep but I was really talkative apparently the
first two nights I remember vaguely talking to my
husband” (Patient 029 - placebo)
“I was worse. I felt I was sleeping worse, had more
weird dreams and less energy from the second
tablet than normal” (Patient 021 – placebo)
4. Discussion
Findings from this qualitative exploration on the experience
of melatonin for the treatment of nocturia for people with
MS revealed a number of effects. Firstly, both melatonin and
matched placebo resulted in a perceived reduction of nocturia
for some. This was thought to have improved the quality of
sleep experienced by participants. Consequently, participants
recalled feeling much more energised during the day as
they reported better cognitive, psychological and physical
functioning. Such improvements weremostly associated with
the administration of melatonin. However, some participants
also revealed a positive experience while taking the placebo.
For these particular participants, the experience of sleep was
subjectively better than it had beenprior to trial participation,
which was thought to have contributed to a feeling of having
more energy during the day. However, for some participants
both drugs were thought to have caused severe fatigue and
tiredness, which ultimately hindered quality of life. In such
situations, a reduction in nocturnal voiding was unlikely to
be viewed as a beneficial improvement and so it appeared
that participants were far keener to reduce their daily fatigue
by improving their sleep than target nocturia. These findings
were particularly important as respondents had felt that
nocturia played a key role in increasing levels of fatigue and
tiredness.
Aspects of this qualitative study ostensibly support previ-
ous findings byObayashi et al. [12] andDrake et al. [13] which
provided significant evidence of a link between endogenous
melatonin secretion and nocturia as well as an association
between exogenous melatonin and nocturia related bother in
non-MS populations. The narrative accounts of participants
within this study similarly suggested that melatonin was
effective in reducing nocturnal voiding and any related
bother. However, it also revealed that for some a placebo
had been similarly influential on perceived improvements.
Furthermore, participants did ultimately document adverse
effects that were thought to be related to melatonin which
increased levels of bother. The participants who felt that
the drug had resulted in increased tiredness and fatigue
stressed that their quality of life had reduced along with
their nocturia.This is particularly significant, as it highlighted
that participants were reluctant to view the intervention
as positive if it increased elements of fatigue. This sup-
ported previous findings [16] that had recognised fatigue
as the most bothersome symptom for individuals with MS;
a point that was repeatedly emphasised throughout these
interviews.
The findings from this qualitative study also provided
more depth to the main trial findings which ultimately
found that a low dose of melatonin did not achieve sig-
nificant reduction in nocturia severity. It appeared that the
way participants perceived their nocturia was important, as
was their perspective on the level to which the symptom
interfered with their lives. Those participants who continued
to wake to pass urine but were able to return to sleep,
perceived nocturia as amild inconvenience, as other elements
of their life were not affected. Similarly, those who reported a
reduction in nocturia alongside a daily feeling of drowsiness
noted that nocturia was again insignificant compared to their
fatigue. This appeared to suggest that, although nocturia
was problematic for this cohort, their key concern was
the ability to experience deep sleep. This concern had also
become apparent through discussions regarding the impact
of nocturia, as all participants noted that it was their ability
to sleep that appeared to have the most impact on their daily
lives.
The present study is novel as it incorporates qualitative
research methods into a largely quantitative drug trial,
which ultimately adds more depth and insight into nocturia
in MS. This is particularly crucial in health research, as
it could unveil information that might not be retrieved
through quantitative assessments alone. Participants’ per-
ceptions towards improved nocturia yet increased fatigue,
for example, revealed the importance of eliciting patient
centred, open-ended responses when attempting to inves-
tigate certain research objectives. Without the inclusion of
this qualitative exploration, there could be a risk of failing
to understand issues that were specific to this particular
cohort, such as dissatisfaction or decreased quality of life
even when nocturia had essentially improved according to
the patient’s perspective. Indeed, Lewin et al. [17] noted
that using qualitative methods in randomised controlled
trials could significantly expand our understanding of the
efficacy of different interventions. Moreover, the current
study also incorporated the views of partners, albeit to
a limited extent, a perspective that is largely missed in
exploratory studies on nocturia. In doing so, this qualita-
tive research specifically revealed the interpersonal effect
that nocturia and fatigue could have on the lives of those
with MS. Furthermore, it provided some insight into the
visible impact of nocturia, fatigue, and potential treatments
by providing details on the effects that were observed by
partners.
It is, however, recognised that this method is not without
limitations. Although the use of qualitative, semistructured
interviews provides a rich exploration, they also rely on
participant recollections, which may be imperfect. In fact,
some interviewees did disclose that they suffered from
memory problems as a consequence of their MS, which
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could have affected the elements of their experience that
they chose to share. Furthermore, participants had stressed
that MS was an unpredictable condition and the changes
that they experienced during the trial may well have been
due to their fluctuating MS rather than the trial itself. It
is acknowledged that the qualitative study explored partic-
ipants’ perceptions on the intervention following the final
visit. To fully explore the effect of treatment, it may have been
beneficial to explore perceptions towards change following
each phase of the trial, which might have elicited more
accurate discussions.
5. Conclusion
This paper presents the first qualitative exploration of using
melatonin for the treatment of nocturia in individuals with
MS. In doing so it sought to investigate participants’ per-
ceptions of living with nocturia as well as the effectiveness
of melatonin as a potential treatment for nocturia. In sum-
mary, the interview data provided an insight into the lived
experience of nocturia and found that alleviating fatigue
is a key concern for people with MS who also experience
nocturia. Participants reported symptomatic changes when
taking either melatonin or a placebo. For some, melatonin
may improve sleep, thus reducing fatigue during the day.
Melatonin and placebo were also reported to have increased
feelings of fatigue among some participants. These findings
could therefore have many implications for practice, as
these personal perspectives have revealed that melatonin
may not be an appropriate treatment for all with nocturia
but may offer benefits for some. Of greater benefit may
be the increased understanding of the interplay between
fatigue and nocturia associated with MS that could be
helpful in informing improved evaluation of nocturia and
its impact among individuals with these symptoms in the
future.
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